Andrea Segreti

@virgilio.it

Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, Italy

Andrea Segreti


            Download Compact PDF  
https://researchid.co/a.segreti

RESEARCH, TEACHING, or OTHER INTERESTS

Cardiology and Cardiovascular Medicine, Respiratory Care
85

Scopus Publications

Scopus Publications

  • Echocardiographic Parameters and Athlete Performance: Associations and Training Profile Comparisons
    Emiliano Guerra, Andrea Segreti, Myriam Carpenito, Martina Ciancio, Lorenzo Guarino, Danilo Ricciardi, Chiara Fossati, Sergio Suma, Nicola Gaibazzi, Renato Rosiello, Corrado Lettieri, Rocco Papalia, Fabio Pigozzi, Giuseppe Boriani, Francesco Grigioni
    Echocardiography, 2026
    Purpose This study investigated standard and advanced echocardiographic parameters in endurance athletes with different training profiles, and their association with exercise performance. Methods Consecutive endurance athletes undergoing cardiological screening or orthopedic evaluation for knee injuries at Campus Bio‐Medico University Hospital underwent advanced echocardiography and cardiopulmonary exercise testing. Athletes were categorized into three groups: (1) Long‐Distance (marathon and ultramarathon runners, n = 30); (2) Mid‐Distance (middle‐distance runners, n = 27); and (3) Detrained (≥ 6 months training interruption, n = 31). Results Left ventricular ejection fraction did not differ among groups. The Long‐Distance group had the highest stroke volume index, followed by the Mid‐Distance and Detrained groups ( p <0.001). Long‐Distance athletes showed lower left ventricular global longitudinal strain ( p = 0.003) and left atrial reservoir strain ( p = 0.003) compared to the other groups, with no differences in right ventricular free wall strain. Myocardial work analysis showed higher work index and constructive work, and lower wasted work, leading to greater global work efficiency in the Long‐Distance group ( p <0.001). In multivariable linear regression analysis, stroke volume index ( β = 1.02, p < 0.001) and global work efficiency ( β = 1.00, p = 0.001) were independently associated with Peak VO 2 , whereas global longitudinal strain was not. Conclusion Advanced echocardiography provides additional insights into the athlete's heart. Myocardial work indices reflect training‐related cardiac adaptations, and left atrial reservoir strain is influenced by training status. These findings, together with the association of stroke volume index and global work efficiency with Peak VO 2 , support the integration of advanced echocardiographic parameters into athlete evaluation and monitoring.
  • High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era
    Nardi Tetaj, Andrea Segreti, Aurora Ferro, Virginia Ligorio, Alberto Spagnolo, Francesco Grigioni
    Genes, 2026
    Inherited cardiomyopathies represent a major cause of ventricular arrhythmias (VA) and sudden cardiac death (SCD), frequently occurring in the absence of advanced systolic dysfunction. Traditional strategies for the primary prevention of SCD have relied predominantly on left ventricular ejection fraction (LVEF), an approach that fails to capture the substantial biological and clinical heterogeneity of non-ischemic cardiomyopathies. Over the past decade, advances in cardiac genetics and cardiac magnetic resonance imaging have identified specific genotypes associated with a disproportionate arrhythmic risk, which often precedes overt ventricular remodeling. The 2023 European Society of Cardiology (ESC) Guidelines on cardiomyopathies formalize this paradigm shift by integrating etiology, myocardial substrate, and electrical phenotype into contemporary risk stratification. In this narrative review, we focus on cardiomyopathy-associated genotypes consistently linked to high arrhythmic risk—LMNA, truncating variants in FLNC, RBM20, PLN p.Arg14del, and desmosomal genes—and examine their molecular mechanisms, phenotypic trajectories, and arrhythmogenic profiles. We discuss how genotype-specific patterns of myocardial fibrosis, conduction disease, and VA inform implantable cardioverter-defibrillator (ICD) decision-making beyond LVEF-based thresholds. By synthesizing genetic, imaging, and clinical evidence in light of ESC 2023 recommendations, this review highlights the evolving role of genotype-informed strategies in the personalized prevention of SCD and underscores remaining gaps in evidence and risk prediction.
  • AI-Enabled Sensor Technologies for Remote Arrhythmic Monitoring in High-Risk Cardiomyopathy Genotypes
    Nardi Tetaj, Andrea Segreti, Francesco Piccirillo, Aurora Ferro, Virginia Ligorio, Alberto Spagnolo, Michele Pelullo, Simone Pasquale Crispino, Francesco Grigioni
    Sensors, 2026
    Inherited cardiomyopathies associated with high-risk genotypes, are characterized by a disproportionate risk of malignant ventricular arrhythmias and sudden cardiac death, often independent of left ventricular systolic dysfunction or advanced structural remodeling. Traditional surveillance strategies based on intermittent electrocardiography and phenotype-driven risk assessment are insufficient to capture the dynamic and often silent progression of electrical instability in these populations. This narrative review evaluates the emerging role of artificial intelligence (AI)-enabled sensor technologies in remote arrhythmic monitoring of genetically defined cardiomyopathy cohorts. Wearable ECG devices, implantable cardiac monitors, multisensor cardiac implantable electronic device algorithms, pulmonary artery pressure sensors, and contact-free systems enable continuous acquisition of electrophysiological and hemodynamic data, generating digital biomarkers that may reflect early arrhythmic vulnerability and subclinical decompensation. AI-driven analytics enhance signal processing, automated event detection, and remote data triage, with the potential to reduce clinical workload while preserving diagnostic sensitivity. However, current evidence predominantly derives from heterogeneous heart failure or general arrhythmia populations, and prospective validation in genotype-specific cohorts remains limited. Key challenges include algorithm generalizability, signal quality in ambulatory environments, data governance, interpretability of AI models, and integration into structured remote-care pathways. The convergence of genotype-informed risk stratification and multimodal AI-enabled sensing represents a promising strategy to transition from reactive device-based protection to proactive, precision-guided arrhythmic prevention. Dedicated genotype-focused studies and standardized digital endpoints are required to support safe and effective implementation in inherited cardiomyopathies.
  • Resting and Exercise Lactate Dynamics in Heart Failure: Guiding Therapeutic Optimization
    Aurora Ferro, Andrea Segreti, Nardi Tetaj, Martina Ciancio, Simone Pasquale Crispino, Riccardo Cricco, Chiara Fossati, Fabio Pigozzi, Francesco Grigioni
    Biomedicines, 2026
    In heart failure (HF), elevated blood lactate levels, particularly during exercise or in advanced disease stages, reflect impaired tissue perfusion and altered metabolic regulation. Beyond its traditional role as a marker of anaerobic metabolism, lactate has emerged as a dynamic indicator of metabolic reserve and ventilatory control. This narrative review summarizes current evidence on lactate dynamics at rest and during exercise, highlighting their pathophysiological and clinical relevance. In HF patients, exercise-induced lactate accumulation occurs earlier and at lower workloads, reflecting impaired oxidative capacity and reduced peripheral oxygen utilization. This phenomenon is closely associated with ventilatory inefficiency, as demonstrated by the relationship between lactate levels and the VE/VCO2 slope during cardiopulmonary exercise testing (CPET). Emerging data suggest that lactate is not only a marker of disease severity but also a potential mediator of chemoreflex activation and abnormal ventilatory responses. Furthermore, both pharmacologic and non-pharmacologic interventions may influence lactate production and utilization, supporting its role as a potential tool for therapeutic monitoring. Overall, the integration of lactate assessment, particularly during exercise, into clinical evaluation may provide additional insight into disease mechanisms, improve risk stratification, and contribute to personalized therapeutic optimization in patients with HF.
  • Diagnostic and Prognostic Value of Arterial Blood Gas and Electrolyte Analyses in Heart Failure
    Nardi Tetaj, Andrea Segreti, Francesco Piccirillo, Michele Pelullo, Simone Pasquale Crispino, Martina Ciancio, Gian Paolo Ussia, Francesco Grigioni
    Reviews in Cardiovascular Medicine, 2026
    Heart failure (HF) is a multifaceted clinical syndrome that frequently precipitates disturbances in perfusion, ventilation, and metabolic regulation, all of which are rapidly detectable through arterial blood gas (ABG) analysis. Meanwhile, clinical markers such as lactate, arterial pH, arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2), bicarbonate, and electrolyte concentrations provide dynamic insight into the pathophysiologic status of patients and can serve as early indicators of decompensation. This review evaluates the clinical significance of key ABG and electrolyte parameters in both acute and chronic HF, emphasizing the prognostic value of the analyses, contribution to risk stratification, and utility in guiding therapy. In acute HF and cardiogenic shock, hyperlactatemia and acidosis are associated with increased mortality and the need for hemodynamic or ventilatory support. Furthermore, electrolyte abnormalities, particularly those involving sodium and potassium, are common and driven by neurohormonal activation, pharmacological therapies, and volume shifts. Therefore, integrating ABG and electrolyte monitoring into routine HF management can enhance diagnostic precision and support timely, targeted interventions. This narrative review synthesizes current evidence and proposes a practical framework for interpreting ABG results in the context of contemporary HF care.
  • Obstructive Sleep Apnea and Coronary Artery Disease: An Overlooked Cardiovascular Risk Factor
    Nardi Tetaj, Andrea Segreti, Michele Pelullo, Virginia Ligorio, Martina Ciancio, Aurora Ferro, Riccardo Cricco, Simone Pasquale Crispino, Gian Paolo Ussia, Francesco Grigioni
    Biomedicines, 2026
    Obstructive sleep apnea syndrome (OSA) is increasingly recognized as a common and clinically relevant comorbidity in coronary artery disease (CAD). Epidemiological studies demonstrate that OSA is highly prevalent among patients with CAD and independently increases the risk of myocardial infarction, accelerated atherosclerosis, and recurrent adverse events. The pathophysiological mechanisms underlying this association include intermittent hypoxia, sympathetic overactivation, oxidative stress, endothelial dysfunction, systemic inflammation, metabolic dysregulation, and pro-prothrombotic changes. These processes converge to promote coronary plaque formation, instability, and ischemia. Clinical evidence indicates that OSA contributes to silent nocturnal ischemia, higher rates of acute coronary syndromes, restenosis after percutaneous coronary intervention, and worse prognosis following myocardial infarction or surgical revascularization. Continuous positive airway pressure (CPAP) therapy improves blood pressure, endothelial function, and surrogate markers of ischemia, but large randomized trials have yielded neutral results on major cardiovascular events, largely due to suboptimal adherence. However, observational studies, however, suggest improved survival in patients who are adherent to CPAP therapy. Lifestyle interventions, particularly weight reduction, remain essential adjunctive strategies. This review synthesizes current evidence, evaluates therapeutic implications, and highlights the need for systematic OSA screening in CAD populations. Future research should focus on patient phenotyping, treatment adherence, and integrated care models to improve cardiovascular outcomes.
  • Electrocardiographic Alterations in Obstructive Sleep Apnea Syndrome: Mechanisms and Clinical Relevance
    Andrea Segreti, Michele Pelullo, Virginia Ligorio, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Simone Pasquale Crispino, Francesco Grigioni
    Life, 2026
    Obstructive Sleep Apnea (OSA) is a highly prevalent yet frequently underdiagnosed disorder strongly associated with cardiovascular morbidity and mortality. It is characterized by recurrent episodes of intermittent hypoxia, intrathoracic pressure swings, and sleep fragmentation that trigger sympathetic hyperactivation, oxidative stress, systemic inflammation, and progressive structural cardiac remodeling. These mechanisms translate into a wide range of electrocardiographic (ECG) abnormalities, including both nocturnal brady- and tachyarrhythmias, as well as daytime conduction and repolarization changes. This narrative review synthesizes current knowledge on ECG manifestations of OSA, encompassing atrial and ventricular ECG characteristics and the burden of supraventricular and ventricular arrhythmias. Emerging evidence suggests that several daytime ECG markers may represent accessible, low-cost indicators of subclinical cardiac remodeling and autonomic imbalance, with potential clinical implications. In addition, there is a rapidly evolving landscape of artificial intelligence applications and wearable-based ECG monitoring for OSA detection and risk stratification. Standardization of ECG-derived markers, validation across diverse populations, and integration into clinical workflows represent key priorities for future research. Recognizing ECG alterations associated with OSA may support earlier diagnosis, improved arrhythmic risk stratification, and more effective multidisciplinary management.
  • Cardiac involvement of Gorlin-Goltz syndrome: new light among the shadows of an old congenital disorder
    Mihail Celeski, Andrea Segreti, Annunziata Nusca, Giuseppe Di Gioia, Raffaele Rinaldi, Gian Paolo Ussia, Francesco Grigioni
    Monaldi Archives for Chest Disease, 2026
    Mutations in the PTCH1, PTCH2, or SUFU genes cause the hereditary, autosomal dominant Gorlin-Goltz syndrome (GGS), which is characterized by high penetrance and variable expressivity. Although its clinical manifestations are primarily marked by multiple basal cell carcinomas, other endocrine, neurological, ophthalmologic, genital, and respiratory alterations have been reported in the literature. Despite the association with cardiac fibromas, cardiovascular involvement is rarely reported. Here, we present a case of a patient with myocarditis of unknown origin, later diagnosed with GGS. We discuss the potential underlying mechanisms of this association, emphasizing the importance of recognizing cardiac manifestations in GGS individuals.
  • Respiratory Support in Cardiogenic Pulmonary Edema: Clinical Insights from Cardiology and Intensive Care
    Nardi Tetaj, Giulia Capecchi, Dorotea Rubino, Giulia Valeria Stazi, Emiliano Cingolani, Antonio Lesci, Andrea Segreti, Francesco Grigioni, Maria Grazia Bocci
    Journal of Cardiovascular Development and Disease, 2026
    Cardiogenic pulmonary edema (CPE) is a life-threatening manifestation of acute heart failure characterized by rapid accumulation of fluid in the interstitial and alveolar spaces, leading to severe dyspnea, hypoxemia, and respiratory failure. The condition arises from elevated left-sided filling pressures that increase pulmonary capillary hydrostatic pressure, disrupt alveolo-capillary barrier integrity, and impair gas exchange. Neurohormonal activation further perpetuates congestion and increases myocardial workload, creating a vicious cycle of hemodynamic overload and respiratory compromise. Respiratory support is a cornerstone of management in CPE, aimed at stabilizing oxygenation, reducing the work of breathing, and facilitating ventricular unloading while definitive therapies, such as diuretics, vasodilators, inotropes, or mechanical circulatory support (MCS), address the underlying cause. Among available modalities, non-invasive ventilation (NIV) with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) has the strongest evidence base in moderate-to-severe CPE, consistently reducing the need for intubation and providing rapid relief of dyspnea. High-flow nasal cannula (HFNC) represents an emerging alternative in patients with moderate hypoxemia or intolerance to mask ventilation, and should be considered an adjunctive option in selected patients with less severe disease or NIV intolerance, although its efficacy in severe presentations remains uncertain. Invasive mechanical ventilation is reserved for refractory cases, while extracorporeal membrane oxygenation (ECMO) and other advanced circulatory support modalities may be necessary in cardiogenic shock. Integration of respiratory strategies with hemodynamic optimization is essential, as positive pressure ventilation favorably modulates preload and afterload, synergizing with pharmacological unloading. Future directions include personalization of ventilatory strategies using advanced monitoring, novel interfaces to improve tolerability, and earlier integration of MCS. In summary, respiratory support in CPE is both a bridge and a decisive therapeutic intervention, interrupting the cycle of hypoxemia and hemodynamic deterioration. A multidisciplinary, individualized approach remains central to improving outcomes in this high-risk population.
  • A noninvasive strategy for multi-disease diagnosis via multi-sensor platform: integrative analysis of five years of exhaled breath–based diagnostics for seven diseases
    Alessandro Zompanti, Giorgio Pennazza, Simone Grasso, Anna Sabatini, Maria Vittoria Di Loreto, Costanza Cenerini, Ludovica La Monica, Luca Vollero, Raffaele Antonelli Incalzi, Claudio Pedone, Panaiotis Finamore, Simone Scarlata, Antonio De Vincentis, Antonio Picardi, Pierfilippo Crucitti, Filippo Longo, Gaetano Rocco, Andrea Segreti, Francesco Grigioni, Marco Santonico
    Frontiers in Bioengineering and Biotechnology, 2026
    Sensors used for collecting high-value physiological and biochemical data strongly support a precision medicine approach, by enabling the integration of these complex datasets with routine clinical outcomes to provide more accurate diagnostic and prognostic evaluations. Building on extensive experience in this field, the authors have developed multi-sensor technologies designed to analyze multiple biological fluids, with a particular focus on exhaled breath both in as it is and processed in liquid media. These technologies have been implemented in a large-scale clinical study involving 863 patients affected by seven different diseases, allowing for the acquisition of heterogeneous data suitable for computational modeling and the identification of disease-related characteristics. By integrating multiple sensors and analyzing diverse breath samples, this work aims to generate a comprehensive reference library of breathprints and thereby advance the clinical applicability of breath analysis. The study demonstrates the potential of this multi-omic, multisensory approach to differentiate healthy individuals from patients with various respiratory, cardiovascular, and metabolic disorders, while pioneering investigations of exhaled breath in liquid media—although conducted on a smaller patient cohort—highlight promising opportunities for technological innovation in multisensory diagnostics. While the overall results support the feasibility and potential impact of this methodology, further research will be required to refine the technique, enlarge patient cohorts, and improve the accuracy and specificity of disease detection.
  • Performance-Enhancing Effects of Inhaled Medications: Implications for Heart, Muscle Function, and Doping Detection in Athletes
    Riccardo Cricco, Andrea Segreti, Emanuele Stirpe, Aurora Ferro, Martina Ciancio, Flavia Cipriani, Chiara Fossati, Gian Paolo Ussia, Fabio Pigozzi, Francesco Grigioni
    Journal of Functional Morphology and Kinesiology, 2025
  • The Use of Myocardial Work in Athletes: A Novel Approach to Assess Cardiac Adaptations and Differentiate Physiological Remodeling from Pathology
    Simona Mega, Chiara Fossati, Andrea Segreti, Riccardo Cricco, Zlatan Lazarevic, Myriam Carpenito, Federica Coletti, Jacopo Valeri, Erika Lemme, Fabio Pigozzi, Francesco Grigioni
    Applied Sciences Switzerland, 2025
  • Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
    Simone Pasquale Crispino, Annunziata Nusca, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Andrea Segreti, Ilaria Cavallari, Mario Sabatino, Luciano Potena, Gian Paolo Ussia, Francesco Grigioni
    Biomolecules, 2025
  • Global Registries and Surveys Programme–Heart Failure (GRASP-HF): Rationale, study design and research implications
    Ovidiu Chioncel, Gianluigi Savarese, Cecile Laroche, Offer Amir, Mariya Tokmakova, Antonio Cannata, Loi Do Doan, Tarek Abdelhameed Nagib Ahmed Kafafy, Jan Krejci, Brenda Moura, Lars Lund, Marianna Adamo, Wendy Guillouche, Maurizio Volterani, Bernard Iung, Marco Metra, and
    European Journal of Heart Failure, 2025
  • From menstrual cycle to pregnancy and motherhood: the tough path to be a female athlete
    Giuseppe Di Gioia, Francesca Vespasiano, Mihail Celeski, Daniela Luvero, Simone Pasquale Crispino, Federica Mango, Lorenzo Buzzelli, Andrea Segreti, Roberto Angioli, Gian Paolo Ussia, Francesco Grigioni, Maria Rosaria Squeo
    Sport Sciences for Health, 2025
  • Athlete's artery: Brachial vascular remodeling in elite athletes practicing different sporting disciplines
    G. Di Gioia, F. Vespasiano, A. Ferrera, A. Segreti, E. Lemme, M.R. Squeo
    Science and Sports, 2025
  • Advancements in Sensor Technology for Monitoring and Management of Chronic Coronary Syndrome
    Riccardo Cricco, Andrea Segreti, Aurora Ferro, Stefano Beato, Gaetano Castaldo, Martina Ciancio, Filippo Maria Sacco, Giorgio Pennazza, Gian Paolo Ussia, Francesco Grigioni
    Sensors, 2025
  • Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical Review
    Aurora Ferro, Andrea Segreti, Simone Pasquale Crispino, Riccardo Cricco, Anna Di Cristo, Martina Ciancio, Fiorella Gurrieri, Gian Paolo Ussia, Francesco Grigioni
    Genes, 2025
  • Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF Registry)
    Stefania Paolillo, Christian Basile, Federica Marzano, Dario Bruzzese, Piergiuseppe Agostoni, Irene Mattavelli, Angelo Aloisio, Pietro Ameri, Martina Solimano, Natale Daniele Brunetti, Paolo Calabrò, Arturo Cesaro, Matteo Cameli, Giulia Elena Mandoli, Erberto Carluccio, Chiara Belardinelli, Stefano Carugo, Laura Casalino, Emilia Chiuini, Deborah Cosmi, Frank Lloyd Dini, Mariafrancesca Di Santo, Gennaro Esposito, Ferdinando Ferrara, Maria Francesca Fierro, Gennaro Galasso, Luca Gallo, Antonella Rispoli, Paola Gargiulo, Francesco Grigioni, Andrea Segreti, Franco Guarnaccia, Natale Guarnaccia, Federico Guerra, Emanuele Cicchirillo, Ciro Indolfi, Mauro Larcher, Adele Lillo, Marco Metra, Roberta Montisci, Maria Francesca Marchetti, Savina Nodari, Francesco Fioretti, Ermanno Nardi, Ugo Oliviero, Alberto Palazzuoli, Giuseppe Patti, Marco Pepe, Filomena Pacelli, Fabrizio Perrone Filardi, Giuseppe Putortì, Giosuè Santoro, Michele Senni, Emilia D'Elia, Paolo Severino, Andrea D'Amato, Simona Soriano, Gianfranco Sinagra, Maddalena Rossi, Monica Franzese, Giovanni Smaldone, Giovanni Battista Zito, Pasquale Perrone Filardi
    Esc Heart Failure, 2025
  • Female athletes: a state-of-the-art review of multiorgan influence of exercise training
    Giuseppe DI GIOIA, Andrea SEGRETI, Mihail CELESKI, Simone P. CRISPINO, Lorenzo BUZZELLI, Federica MANGO, Armando FERRERA, Maria R. SQUEO, Francesca VESPASIANO, Gian P. USSIA, Francesco GRIGIONI
    Journal of Sports Medicine and Physical Fitness, 2025
  • Hemodynamic Effects of Positive Airway Pressure: A Cardiologist’s Overview
    Anna Di Cristo, Andrea Segreti, Nardi Tetaj, Simone Pasquale Crispino, Emiliano Guerra, Emanuele Stirpe, Gian Paolo Ussia, Francesco Grigioni
    Journal of Cardiovascular Development and Disease, 2025
  • The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
    Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, Daniele Valente, Filippo Crisci, Aurora Ferro, Ilaria Cavallari, Annunziata Nusca, Gian Paolo Ussia, Francesco Grigioni
    Biomedicines, 2025
  • Relevant medical conditions affecting sports participation
    Paolo Borrione, Paolo Sgrò, Arrigo Giombini, Andrea Segreti, Juergen M. Steinacker, Fabio Pigozzi
    Sports Physician Handbook, 2025
  • The current paradigm of cardiac troponin increase among athletes
    Mihail Celeski, Andrea Segreti, Mariagrazia Piscione, Luigi Maria Monticelli, Giuseppe Di Gioia, Chiara Fossati, Gian Paolo Ussia, Fabio Pigozzi, Francesco Grigioni
    Monaldi Archives for Chest Disease, 2025
  • Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments
    Andrea Segreti, Sara Mastroberardino, Lorenzo Frau, Alessandro Appetecchia, Luca D’Antonio, Danilo Ricciardi, Gian Paolo Ussia, Francesco Grigioni
    Monaldi Archives for Chest Disease, 2025
  • The diagnostic accuracy of contemporary ECG interpretation criteria in risk stratification of master athletes
    Geza Halasz, Bruno Capelli, Simone Pasquale Crispino, Andrea Segreti, Raffaella Mistrulli, Federico Andreoli, Armando Ferrera, Francesco Perone, Michele Villa, Tiziano Cassina, Vincenzo Biasini, Francesco Grigioni, Domenico Gabrielli, Massimo Piepoli
    Frontiers in Cardiovascular Medicine, 2025
  • Heart, lungs, and statins: is it an easy cohabitation? Pitfalls and controversies
    Dajana POLITO, Andrea SEGRETI, Mariagrazia PISCIONE, Francesca VESPASIANO, Vincenzo NAFISIO, Ilaria CAVALLARI, Gian P. USSIA, Raffaele ANTONELLI-INCALZI, Francesco GRIGIONI
    Minerva Respiratory Medicine, 2024
  • The Role of Cardiac Troponin and Other Emerging Biomarkers Among Athletes and Beyond: Underlying Mechanisms, Differential Diagnosis, and Guide for Interpretation
    Mihail Celeski, Andrea Segreti, Filippo Crisci, Riccardo Cricco, Mariagrazia Piscione, Giuseppe Di Gioia, Annunziata Nusca, Chiara Fossati, Fabio Pigozzi, Gian Paolo Ussia, Ross John Solaro, Francesco Grigioni
    Biomolecules, 2024
  • The Complementary Role of Cardiopulmonary Exercise Testing in Coronary Artery Disease: From Early Diagnosis to Tailored Management
    Simone Pasquale Crispino, Andrea Segreti, Martina Ciancio, Dajana Polito, Emiliano Guerra, Giuseppe Di Gioia, Gian Paolo Ussia, Francesco Grigioni
    Journal of Cardiovascular Development and Disease, 2024
  • Determinants of supraventricular extra beats in elite athletes practicing different sporting disciplines
    Giuseppe Di Gioia, Francesca Vespasiano, Viviana Maestrini, Sara Monosilio, Andrea Segreti, Erika Lemme, Maria Rosaria Squeo, Andrea Serdoz, Antonio Pelliccia
    Journal of Cardiovascular Medicine, 2024
  • Breath Analysis via Gas Chromatography–Mass Spectrometry (GC-MS) in Chronic Coronary Syndrome (CCS): A Proof-of-Concept Study
    Marco Lombardi, Andrea Segreti, Marco Miglionico, Giorgio Pennazza, Lorenzo Tocca, Luca Amendola, Rocco Vergallo, Germano Di Sciascio, Italo Porto, Francesco Grigioni, Raffaele Antonelli Incalzi
    Journal of Clinical Medicine, 2024
  • Athlete’s ECG Made Easy: A Practical Guide to Surviving Everyday Clinical Practice
    Valerio Fanale, Andrea Segreti, Chiara Fossati, Giuseppe Di Gioia, Federica Coletti, Simone Pasquale Crispino, Francesco Picarelli, Raffaele Antonelli Incalzi, Rocco Papalia, Fabio Pigozzi, Francesco Grigioni
    Journal of Cardiovascular Development and Disease, 2024
  • The Spectrum of Coronary Artery Disease in Elite Endurance Athletes—A Long-Standing Debate: State-of-the-Art Review
    Mihail Celeski, Giuseppe Di Gioia, Annunziata Nusca, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Federica Mango, Armando Ferrera, Gian Paolo Ussia, Francesco Grigioni
    Journal of Clinical Medicine, 2024
  • Lack of cardiac remodelling in elite endurance athletes: an unexpected and not so rare finding
    Giuseppe Di Gioia, Simone Pasquale Crispino, Viviana Maestrini, Sara Monosilio, Davide Ortolina, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Antonio Nenna, Antonio Pelliccia
    European Journal of Applied Physiology, 2024
  • Long-Term Evaluation of Lipid Profile Changes in Olympic Athletes
    Giuseppe Di Gioia, Lorenzo Buzzelli, Viviana Maestrini, Maria Rosaria Squeo, Erika Lemme, Sara Monosilio, Andrea Serdoz, Roberto Fiore, Domenico Zampaglione, Andrea Segreti, Antonio Pelliccia
    International Journal of Sport Nutrition and Exercise Metabolism, 2024
  • Changes in Cardiopulmonary Capacity Parameters after Surgery: A Pilot Study Exploring the Link between Heart Function and Knee Surgery
    Andrea Segreti, Chiara Fossati, Luigi Maria Monticelli, Daniele Valente, Dajana Polito, Emiliano Guerra, Andrea Zampoli, Giorgio Albimonti, Biagio Zampogna, Sebastiano Vasta, Rocco Papalia, Raffaele Antonelli Incalzi, Fabio Pigozzi, Francesco Grigioni
    Journal of Functional Morphology and Kinesiology, 2024
  • Effects of Environmental Conditions on Athlete’s Cardiovascular System
    Andrea Segreti, Mihail Celeski, Emiliano Guerra, Simone Pasquale Crispino, Francesca Vespasiano, Lorenzo Buzzelli, Chiara Fossati, Rocco Papalia, Fabio Pigozzi, Francesco Grigioni
    Journal of Clinical Medicine, 2024
  • Electrocardiographic alterations in chronic obstructive pulmonary disease
    Daniele Valente, Andrea Segreti, Mihail Celeski, Dajana Polito, Luisa Vicchio, Giuseppe Di Gioia, Gian Paolo Ussia, Raffaele Antonelli-Incalzi, Francesco Grigioni
    Journal of Electrocardiology, 2024
  • Assessment of cardiopulmonary capacity in deconditioned athletes because of knee injury
    Andrea SEGRETI, Chiara FOSSATI, Maria T. MULÈ, Valerio FANALE, Simone P. CRISPINO, Federica COLETTI, Francesco R. PARISI, Biagio ZAMPOGNA, Sebastiano VASTA, Elena MANNACIO, Rocco PAPALIA, Raffaele ANTONELLI-INCALZI, Fabio PIGOZZI, Francesco GRIGIONI
    Journal of Sports Medicine and Physical Fitness, 2024
  • Traditional and Advanced Echocardiographic Evaluation in Chronic Obstructive Pulmonary Disease: The Forgotten Relation
    Mihail Celeski, Andrea Segreti, Dajana Polito, Daniele Valente, Luisa Vicchio, Giuseppe Di Gioia, Gian Paolo Ussia, Raffaele Antonelli Incalzi, Francesco Grigioni
    American Journal of Cardiology, 2024
  • Eosinophilic Myocarditis: From Bench to Bedside
    Francesco Piccirillo, Sara Mastroberardino, Vincenzo Nafisio, Matteo Fiorentino, Andrea Segreti, Annunziata Nusca, Gian Paolo Ussia, Francesco Grigioni
    Biomedicines, 2024
  • Left ventricular inferior wall congenital diverticula in athletes: a case series and review of the literature
    Giuseppe Di Gioia, Lorenzo Buzzelli, Andrea Segreti
    European Heart Journal Case Reports, 2024
  • Alternative lipid lowering strategies: State-of-the-art review of red yeast rice
    Lorenzo Buzzelli, Andrea Segreti, Daniela Di Gioia, Erika Lemme, Maria Rosaria Squeo, Antonio Nenna, Giuseppe Di Gioia
    Fitoterapia, 2024
  • A sudden right-to-left shunt: the importance of evaluating patent foramen ovale during exercise
    Simone Pasquale Crispino, Andrea Segreti, Ylenia La Porta, Paola Liporace, Myriam Carpenito, Valeria Cammalleri, Francesco Grigioni
    Monaldi Archives for Chest Disease, 2024
  • Simultaneous presence of Brugada and overgrowth syndromes
    Andrea Segreti, Francesco Piccirillo, Simone Pasquale Crispino, Francesca Cocchia, Arianna Martucciello, Vito Calabrese, Fiorella Gurrieri, Francesco Grigioni
    Monaldi Archives for Chest Disease, 2024
  • Influence of isometric versus isotonic exercise training on right ventricular morpho-functional parameters in Olympic athletes
    Giuseppe Di Gioia, Dajana Polito, Simone Pasquale Crispino, Viviana Maestrini, Antonio Nenna, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Antonio Pelliccia
    Echocardiography, 2024
  • Influence of the Type of Disability and Sporting Discipline on Lipid Profile in a Cohort of Italian Paralympic Athletes
    Giuseppe Di Gioia, Federica Coletti, Lorenzo Buzzelli, Viviana Maestrini, Sara Monosilio, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Antonio Nenna, Antonio Pelliccia
    American Journal of Cardiology, 2024
  • Prevalence of Hyperuricemia and Associated Cardiovascular Risk Factors in Elite Athletes Practicing Different Sporting Disciplines: A Cross-Sectional Study
    Giuseppe Di Gioia, Simone Pasquale Crispino, Viviana Maestrini, Sara Monosilio, Maria Rosaria Squeo, Erika Lemme, Andrea Segreti, Andrea Serdoz, Roberto Fiore, Domenico Zampaglione, Antonio Pelliccia
    Journal of Clinical Medicine, 2024
  • Cardiovascular and metabolic effects of hyperbilirubinemia in a cohort of Italian Olympic athletes
    Giuseppe Di Gioia, Simone Pasquale Crispino, Sara Monosilio, Viviana Maestrini, Antonio Nenna, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Gian Paolo Ussia, Francesco Grigioni, Antonio Pelliccia
    Scandinavian Journal of Medicine and Science in Sports, 2023
  • Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
    Ilaria Cavallari, Simone Pasquale Crispino, Andrea Segreti, Gian Paolo Ussia, Francesco Grigioni
    American Journal of Cardiovascular Drugs, 2023
  • Athlete's heart or heart disease in the athlete? Evaluation by cardiopulmonary exercise testing
    Andrea SEGRETI, Francesco PICARELLI, Giuseppe DI GIOIA, Federica COLETTI, Simone P. CRISPINO, Valerio FANALE, Chiara FOSSATI, Raffaele ANTONELLI INCALZI, Fabio PIGOZZI, Francesco GRIGIONI
    Journal of Sports Medicine and Physical Fitness, 2023
  • A State-of-the-Art Review on Sleep Apnea Syndrome and Heart Failure
    Francesco Piccirillo, Simone Pasquale Crispino, Lorenzo Buzzelli, Andrea Segreti, Raffaele Antonelli Incalzi, Francesco Grigioni
    American Journal of Cardiology, 2023
  • Mitral and Tricuspid Valve Disease in Athletes
    Andrea Segreti, Mihail Celeski, Luigi Maria Monticelli, Alfonso Perillo, Simone Pasquale Crispino, Giuseppe Di Gioia, Valeria Cammalleri, Chiara Fossati, Simona Mega, Rocco Papalia, Fabio Pigozzi, Gian Paolo Ussia, Francesco Grigioni
    Journal of Clinical Medicine, 2023
  • Reversible Apical Hypertrophy in a Young Competitive Athlete with Familiar Hypertrophic Cardiomyopathy
    Giuseppe Di Gioia, Viviana Maestrini, Alessandra Colella, Ruggiero Mango, Andrea Segreti, Maria Rosaria Squeo, Erika Lemme, Antonio Pelliccia
    American Journal of Case Reports, 2023
  • Listing Criteria for Heart Transplant: Role of Cardiopulmonary Exercise Test and of Prognostic Scores
    Andrea Segreti, Giuseppe Verolino, Simone Pasquale Crispino, Piergiuseppe Agostoni
    Heart Failure Clinics, 2021
  • Chemoreceptor hyperactivity in heart failure: Is lactate the culprit?
    Andrea Segreti, Francesco Grigioni, Jeness Campodonico, Alessandra Magini, Denise Zaffalon, Gianfranco Sinagra, Germano Di Sciascio, Erik Richard Swenson, Piergiuseppe Agostoni
    European Journal of Preventive Cardiology, 2021
  • Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma
    Bruno Sposato, Marco Scalese, Alberto Ricci, Paola Rogliani, Pierluigi Paggiaro, B. Sposato, M. G. Migliorini, M. Di Tomassi, C. Olivieri, A. Perrella, G. Camiciottoli, R. Maselli, G. Pelaia, M. T. Busceti, E. Sabato, M. G. Cagnazzo, F. Colombo, L. Palumbo, A. Ravazzi, C. Bucca, M. F. Caiaffa, A. Berra, C. Calabrese, A. A. Stanziola, P. Schino, M. Di Gioacchino, P. Rogliani, M. Cazzola, A. Segreti, E. A. Pastorello, G. Scibilia, A. Vianello, M. R. Marchi, L. Paladini, S. Baglioni, M. Abbritti, F. Almerigogna, A. Matucci, A. Vultaggio, E. Maggi, P. Maestrelli, G. Guarnieri, G. Steinhilber, M Bonavia, P. Rottoli, E. Bargagli, G. Senna, M. Caminati, L. Macchia, V. Bellia, N. Scichilone, P. Paggiaro, F. Novelli, M. Latorre, L. Vergura, S. Masieri, M. Scalese, Y. Rosati, M. Milanese, I. Folletti, R. Pio, A. Pio, U. Maccari, C. Maggiorelli, R. Scala, L. Vignale, N. Pulerà, G. E. Carpagnano, M. P. Foschino Barbaro, and
    Clinical Respiratory Journal, 2021
  • Characterization of inflammatory profile by breath analysis in chronic coronary syndromes
    Andrea Segreti, Raffaele Antonelli Incalzi, Marco Lombardi, Marco Miglionico, Annunziata Nusca, Giorgio Pennazza, Marco Santonico, Simone Grasso, Francesco Grigioni, Germano Di Sciascio
    Journal of Cardiovascular Medicine Hagerstown Md, 2020
  • Current diagnostic ECG criteria for left ventricular hypertrophy: Is it time to change paradigm in the analysis of data?
    Danilo Ricciardi, Giampaolo Vetta, Antonio Nenna, Francesco Picarelli, Antonio Creta, Andrea Segreti, Camilla Cavallaro, Myriam Carpenito, Flavio Gioia, Natale Di Belardino, Mario Lusini, Massimo Chello, Vito Calabrese, Francesco Grigioni
    Journal of Cardiovascular Medicine, 2020
  • Percutaneous Left Atrial Appendage Closure: Acute Effects on Left Atrial Pressure in Humans
    Giuseppe Patti, Antonio Rapacciuolo, Andrea Segreti, Gian Paolo Ussia, Costanza Goffredo, Germano Di Sciascio
    Jacc Cardiovascular Interventions, 2019
  • Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
    Bruno Sposato, Marco Scalese, Manlio Milanese, Simonetta Masieri, Carlo Cavaliere, Manuela Latorre, Nicola Scichilone, Alberto Ricci, Alberto Cresti, Pierachille Santus, Carmela Olivieri, Antonio Perrella, Paola Rogliani, Pierluigi Paggiaro, B. Sposato, M.G. Migliorini, M. Di Tomassi, C. Olivieri, A. Perrella, G. Camiciottoli, R. Maselli, G. Pelaia, M.T. Busceti, E. Sabato, M.G. Cagnazzo, F. Colombo, L. Palumbo, A. Ravazzi, C. Bucca, M.F. Caiaffa, A. Berra, C. Calabrese, A.A. Stanziola, P. Schino, M. Di Gioacchino, P. Rogliani, M. Cazzola, A. Segreti, E.A. Pastorello, G. Scibilia, A. Vianello, M.R. Marchi, L. Paladini, S. Baglioni, M. Abbritti, F. Almerigogna, A. Matucci, A. Vultaggio, E. Maggi, P. Maestrelli, G. Guarnieri, G. Steinhilber, M. Bonavia, P. Rottoli, E. Bargagli, G. Senna, M. Caminati, L. Macchia, V. Bellia, N. Scichilone, P. Paggiaro, F. Novelli, M. Latorre, L. Vergura, S. Masieri, M. Scalese, Y. Rosati, M. Milanese, I. Folletti, R. Pio, A. Pio, U. Maccari, C. Maggiorelli, R. Scala, L. Vignale, N. Pulerà, G.E. Carpagnano, M.P. Foschino Barbaro
    Journal of Allergy and Clinical Immunology in Practice, 2019
  • Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi
    Paola Rogliani, Luigino Calzetta, Josuel Ora, Roberto Lipsi, Andrea Segreti, Maria Gabriella Matera, Mario Cazzola
    European Journal of Pharmacology, 2015
  • Translational study searching for synergy between glycopyrronium and indacaterol
    Mario Cazzola, Luigino Calzetta, Andrea Segreti, Francesco Facciolo, Paola Rogliani, Maria Gabriella Matera
    Copd Journal of Chronic Obstructive Pulmonary Disease, 2015
  • Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy
    Federica Novelli, Manuela Latorre, Letizia Vergura, Maria Filomena Caiaffa, Gianna Camiciottoli, Gabriella Guarnieri, Andrea Matucci, Luigi Macchia, Andrea Vianello, Alessandra Vultaggio, Alessandro Celi, Mario Cazzola, Pierluigi Paggiaro
    Pulmonary Pharmacology and Therapeutics, 2015
  • Analysis of exhaled breath fingerprints and volatile organic compounds in COPD
    Mario Cazzola, Andrea Segreti, Rosamaria Capuano, Alberto Bergamini, Eugenio Martinelli, Luigino Calzetta, Paola Rogliani, Chiara Ciaprini, Josuel Ora, Roberto Paolesse, Corrado Di Natale, Arnaldo D’Amico
    Copd Research and Practice, 2015
  • The clinical use of regenerative therapy in COPD
    Mario Cazzola, Roberto Lipsi, Andrea Segreti, Luigino Calzetta, Paola Rogliani
    International Journal of Copd, 2014
  • Umeclidinium for the treatment of chronic obstructive pulmonary disease
    Andrea Segreti, Luigino Calzetta, Paola Rogliani, Mario Cazzola
    Expert Review of Respiratory Medicine, 2014
  • Diabetes mellitus among outpatients with COPD attending a university hospital
    Paola Rogliani, Luigino Calzetta, Andrea Segreti, Annapina Barrile, Mario Cazzola
    Acta Diabetologica, 2014
  • Omalizumab: Stepping outside our comfort zone to broaden the number of those who can benefit
    Mario Cazzola, Andrea Segreti
    Drugs, 2014
  • Defining phenotypes in COPD: An aid to personalized healthcare
    Andrea Segreti, Emanuele Stirpe, Paola Rogliani, Mario Cazzola
    Molecular Diagnosis and Therapy, 2014
  • The effect of indacaterol during an acute exacerbation of COPD
    Andrea Segreti, Enrica Fiori, Luigino Calzetta, Marco Sabatini, Vincenzo Segreti, Paola Rogliani, Mario Cazzola
    Pulmonary Pharmacology and Therapeutics, 2013
  • New developments in the combination treatment of COPD: Focus on umeclidinium/vilanterol
    Mario Cazzola, Andrea Segreti, Maria Gabriella Matera
    Drug Design Development and Therapy, 2013
  • Chronic treatment with indacaterol and airway response to salbutamol in stable COPD
    Mario Cazzola, Paola Rogliani, Paolo Ruggeri, Andrea Segreti, Alfio Proietto, Stefano Picciolo, Maria Gabriella Matera
    Respiratory Medicine, 2013
  • Comorbidities of asthma: Current knowledge and future research needs
    Mario Cazzola, Andrea Segreti, Luigino Calzetta, Paola Rogliani
    Current Opinion in Pulmonary Medicine, 2013
  • Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol
    Mario Cazzola, Andrea Segreti, Emanuele Stirpe, Ermanno Puxeddu, Josuel Ora, Paola Rogliani, Maria Gabriella Matera
    Respiratory Medicine, 2013
  • Comparative effectiveness of drugs for chronic obstructive pulmonary disease
    M. Cazzola, A. Segreti, P. Rogliani
    Drugs of Today, 2012
  • An update on bronchodilators in Phase i and II clinical trials
    Mario Cazzola, Paola Rogliani, Andrea Segreti, Maria Gabriella Matera
    Expert Opinion on Investigational Drugs, 2012
  • Emerging drugs for chronic obstructive pulmonary disease
    Maria Gabriella Matera, Luigino Calzetta, Andrea Segreti, Mario Cazzola
    Expert Opinion on Emerging Drugs, 2012
  • COPD identification by the analysis of breath with an electronic nose
    Rosamaria Capuano, Marco Santonico, Eugenio Martinelli, Roberto Paolesse, Alberto Bergamini, Mario Cazzola, Chiara Ciaprini, Andrea Segreti, Corrado Di Natale, Arnaldo D’Amico, Perena Gouma
    Aip Conference Proceedings, 2011
  • Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008
    Mario Cazzola, Andrea Segreti, Germano Bettoncelli, Luigino Calzetta, Claudio Cricelli, Franco Pasqua, Paola Rogliani
    Primary Care Respiratory Journal, 2011
  • The prevalence of asthma and COPD in Italy: A practice-based study
    Mario Cazzola, Ermanno Puxeddu, Germano Bettoncelli, Lucia Novelli, Andrea Segreti, Claudio Cricelli, Luigino Calzetta
    Respiratory Medicine, 2011
  • Energy expenditure and impact of bronchodilators in COPD patients
    Mario Cazzola, Andrea Segreti, Emanuele Stirpe, Massimiliano Appodia, Lucia Senis, Maria G. Matera
    Respiratory Medicine, 2010
  • Novel bronchodilators in asthma
    Mario Cazzola, Andrea Segreti, Maria G Matera
    Current Opinion in Pulmonary Medicine, 2010
  • A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD
    Mario Cazzola, Paola Rogliani, Giacomo Curradi, Andrea Segreti, Chiara Ciaprini, Gabriella Pezzuto, Cesare Saltini
    Pulmonary Pharmacology and Therapeutics, 2009
  • Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome?
    M. Cazzola, M. Mura, A. Segreti, M. A. Mattei, P. Rogliani
    Allergy European Journal of Allergy and Clinical Immunology, 2009